Advertisement

Topics

Experimental sickle cell disease drug gets PRIME status

05:38 EDT 29 Jun 2017 | PharmaTimes

Global Blood Therapeutics’ GBT440 has become the first potential treatment for sickle cell disease to be accepted onto the European Medicines Agency’s regulatory support programme PRIME.

Original Article: Experimental sickle cell disease drug gets PRIME status

NEXT ARTICLE

More From BioPortfolio on "Experimental sickle cell disease drug gets PRIME status"

Advertisement
Quick Search
Advertisement
Advertisement